54,836 Shares in CVRx, Inc. (NASDAQ:CVRX) Purchased by Tradewinds LLC.

Tradewinds LLC. bought a new stake in shares of CVRx, Inc. (NASDAQ:CVRX) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 54,836 shares of the company’s stock, valued at approximately $695,000.

A number of other large investors have also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp boosted its stake in shares of CVRx by 4.5% during the 4th quarter. Bank of New York Mellon Corp now owns 30,377 shares of the company’s stock worth $385,000 after acquiring an additional 1,296 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of CVRx by 36.1% during the third quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock valued at $168,000 after acquiring an additional 5,053 shares during the period. Geode Capital Management LLC lifted its holdings in shares of CVRx by 2.2% in the third quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock valued at $2,600,000 after purchasing an additional 6,443 shares in the last quarter. Calamos Advisors LLC acquired a new position in CVRx during the fourth quarter valued at $134,000. Finally, Barclays PLC increased its stake in CVRx by 312.5% in the 3rd quarter. Barclays PLC now owns 19,067 shares of the company’s stock valued at $169,000 after buying an additional 14,445 shares during the period. 75.27% of the stock is currently owned by institutional investors.

CVRx Trading Down 2.1 %

Shares of CVRx stock opened at $12.23 on Tuesday. The stock has a market capitalization of $318.42 million, a P/E ratio of -4.55 and a beta of 1.34. CVRx, Inc. has a 12-month low of $6.40 and a 12-month high of $19.24. The company has a 50-day simple moving average of $13.92 and a 200 day simple moving average of $12.88. The company has a quick ratio of 10.23, a current ratio of 12.06 and a debt-to-equity ratio of 0.69.

CVRx (NASDAQ:CVRX) last issued its quarterly earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%. Research analysts expect that CVRx, Inc. will post -1.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have weighed in on CVRX. Canaccord Genuity Group upped their target price on CVRx from $22.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, February 5th. Piper Sandler increased their price objective on CVRx from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, February 5th. Craig Hallum boosted their target price on CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, January 17th. Finally, William Blair upgraded shares of CVRx from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $17.83.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.